Placeholder Banner

BIO Submits Comments on FDA Draft Guidance for the Development of Non-Opioid Analgesics for Acute Pain

April 11, 2022

On Monday, April 11th, BIO submitted comments in response to the FDA’s recent draft guidance on the Development of Non-Opioid Analgesics for Acute Pain. In the comments submitted, BIO reaffirmed its commitment to working with the Agency to achieve its stated priority of “fostering the development of novel non-opioid analgesics.” Additionally, BIO proposed several recommendations for improving the draft guidance. For example, BIO urged the FDA to prioritize implementation of policy that promotes efficient and effective development of non-opioid analgesics to support a general acute pain indication and encouraged the Agency to expedite efforts to publish policy on development of non-opioid analgesics for chronic pain as well.

Most notably, BIO expressed concern that the FDA is setting a higher bar for the development of analgesics with novel mechanisms of action (MOA) by stating a likely requirement for “clinical trials in more than two different pain populations to support a general acute pain indication.” This language contradicts previous policy for the basis of approval and counters regulatory precedent. Furthermore, BIO highlighted that using the MOA as the determinant obscures the evidentiary standard. Assuming there is clear rationale for the drug and good grounding in biology, BIO strongly recommended the Agency hold any non-opioid for acute pain, whether a novel MOA or not, to the same evidentiary standard of two studies. 

Download Full Comments Below
BIO COMMENT LETTER Development of Non Opioid Analgesics for Acute Pain
Discover More
On Monday, June 13th, BIO submitted comments in response to a recently published FDA draft guidance providing recommendations to sponsors on developing a Race and Ethnicity Diversity Plan to enroll adequate numbers of participants in clinical trials…
On Friday, June 10th, BIO submitted comments in response to the FDA’s draft guidance on developing human gene therapy products that incorporate genome editing (GE) of human somatic cells. Overall, BIO found the guidance to be a well-written resource…
On Friday, June 10th, BIO submitted comments in response to the FDA’s draft guidance on Chimeric antigen receptor (CAR) T cell products (i.e., human gene therapy products in which the T cell specificity is genetically modified to enable recognition…